Us Bancorp \De\ Protagonist Therapeutics, Inc Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Us Bancorp \De\ holds 7,866 shares of PTGX stock, worth $374,578. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,866

Previous 8,567 8.18%

Holding current value

$374,578

Previous $296,000 19.26%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$33.72 - $47.33 $23,637 - $33,178	-701 Reduced 8.18%	7,866 $353,000
Q2 2024 Aug 06, 2024	BUY	$24.66 - $34.8 $56,249 - $79,378	2,281 Added 36.29%	8,567 $296,000
Q1 2024 May 07, 2024	SELL	$21.79 - $32.15 $19,196 - $28,324	-881 Reduced 12.29%	6,286 $181,000
Q4 2023 Feb 09, 2024	SELL	$14.05 - $23.44 $38,539 - $64,295	-2,743 Reduced 27.68%	7,167 $164,000
Q3 2023 Nov 03, 2023	BUY	$16.68 - $23.66 $164,648 - $233,547	9,871 Added 25310.26%	9,910 $165,000
Q2 2023 Aug 09, 2023	BUY	$18.02 - $29.36 $702 - $1,145	39 New	39 $1,000
Q3 2022 Oct 27, 2022	BUY	$7.86 - $11.71 $8,740 - $13,021	1,112 New	1,112 $9,000
Q2 2022 Aug 01, 2022	SELL	$7.06 - $25.52 $3,318 - $11,994	-470 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$23.34 - $36.08 $4,481 - $6,927	192 Added 69.06%	470 $11,000
Q4 2021 Feb 11, 2022	BUY	$17.63 - $37.1 $246 - $519	14 Added 5.3%	278 $10,000
Q3 2021 Nov 10, 2021	SELL	$12.95 - $49.69 $1,178 - $4,521	-91 Reduced 25.63%	264 $4,000
Q1 2021 Apr 28, 2021	SELL	$19.02 - $31.15 $1,388 - $2,273	-73 Reduced 17.06%	355 $9,000
Q4 2020 Feb 04, 2021	BUY	$18.49 - $25.13 $6,785 - $9,222	367 Added 601.64%	428 $9,000
Q2 2020 Aug 07, 2020	BUY	$6.19 - $18.84 $377 - $1,149	61 New	61 $1,000

Others Institutions Holding PTGX

# of Institutions

212

Shares Held

59.1M

Call Options Held

19K

Put Options Held

107K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.34B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account